ArticleJournal of oral and maxillofacial pathology : JOMFP
Evaluation of salivary vimentin in oral erosive lichen planus, oral leukoplakia, oral squamous cell carcinoma and healthy subjects using ELISA.
Article in Journal of oral and maxillofacial pathology : JOMFP. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Oral cancer is the sixth most common cancer globally. In India, 80% of oral cancers are preceded by oral potentially malignant disorders (OPMDs). The conditions with mild dysplasia go unrecognised and may eventually transform into severe dysplasia and ultimately to malignant lesions. Hence, the development of biomarkers that will serve as an adjunct to histological diagnosis has become essential. Aim: The present study undertaken to assess the salivary levels of vimentin, being non-invasive as early biomarker for malignant transformation of OPMDs. Settings and Design: Cross-sectional study, participants were selected from the Departments of Oral Medicine and Radiology and Oral Pathology and Microbiology of Azeezia College of Dental Sciences and Research, Kollam. Methods and Materials: The salivary vimentin expression levels were detected using ELISA and were correlated with oral erosive lichen planus, oral leukoplakia, oral squamous cell carcinoma (OSCC) patients and healthy individuals. The association of salivary vimentin levels with clinical severity of oral erosive lichen planus, clinical types of leukoplakia, and clinical staging of OSCC. and also, the relationship between different grades of epithelial dysplasia in leukoplakia patients and histopathological grades of OSCC was assessed. Statistical Analysis Used: Data were analysed using the statistical package SPSS 26.0 (SPSS Inc., Chicago, IL, USA). Descriptive statistics were performed to estimate the mean, standard deviation, proportion of the respective groups. Kruskal-Wallis test followed by Tukey's HSD Results: The results showed that salivary vimentin can be used as a biomarker for predicting malignant transformation of oral leukoplakia and oral erosive lichen planus. The study showed a statistically significant correlation between oral erosive lichen planus, oral leukoplakia and oral cancer and control groups regarding salivary vimentin levels, also there is a statistically significant correlation of salivary vimentin with OSCC histopathological grades and OSCC Clinical Staging. Conclusion: The present study showed that salivary vimentin can be used as a biomarker for predicting malignant transformation of oral leukoplakia and oral erosive lichen planus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.